Expected costs, days of life gained, and incremental cost-effectiveness of screening for cough followed by triage testing for tuberculosis, per patient presenting with prolonged cough to a healthcare facility in Uganda
Strategy | Average cost (2014 US$) | Incremental cost (2014 US$) | Average years of life lived | Incremental days of life gained | ICER (US$/YLG) | Uncertainty range |
---|---|---|---|---|---|---|
Standard of care | US$18.23 | – | 17.417 | – | – | – |
CRP | US$24.30 | US$6.07 | 17.427 | 3.7 days | US$588 | US$221–US$1746 |
CXR | US$24.52 | US$6.29 | 17.427 | 3.7 days | US$610 | US$200–US$1859 |
Incremental effectiveness and cost-effectiveness for both CRP and CXR are presented relative to the standard of care scenario.
CRP, C reactive protein; CXR, chest X-ray; ICER, incremental cost-effectiveness ratio; YLG, year of life gained.